Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02799095 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
A Phase 1 study, sponsored by Mural Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 243
- Enrollment target
NCT02799095: Completed Phase 1 study, sponsored by Mural Oncology.
NCT02799095 is a Phase 1 study that has completed, run by Mural Oncology. The registered enrollment target is 243 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (305% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02799095, a Phase 1 study, has completed, sponsored by Mural Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 243 participants
- Enrollment target
Study Summary
To better understand the safety and tolerability of ALKS 4230 in humans
Primary Outcome
DLT was defined by any of following events possibly, probably, or definitely related to ALKS 4230: Grade 4 neutrophil count decreased (neutropenia); Febrile neutropenia; CTCAE Grade 4 thrombocytopenia; Thrombocytopenia; Any Grade 3 cardiac or central nervous system toxicity; Liver transaminase elevation higher than 8\*upper limit of normal (ULN) or total bilirubin higher than 6\*ULN; Grade 4 hypoalbuminemia; Fever more than (\>) 40 degree Celsius (°C) sustained for \>24 hours; Hypotension requir
Interventions
- DRUG ALKS 4230
- DRUG ALKS 4230 + pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2016-09-14 |
| Est. Completion | 2023-08-02 |
| Phase | Phase 1 |
What the finished NCT02799095 record still lists
NCT02799095 is an interventional study that assigns participants to a tested intervention. The registered 243 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (305% higher).
The record links to 0 conditions, and to 2 interventions - of which ALKS 4230 is the first listed.
NCT02799095 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02799095 about?
NCT02799095 is a clinical study titled "A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors". To better understand the safety and tolerability of ALKS 4230 in humans
What is the current status of trial NCT02799095?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 243 participants. The study started on 2016-09-14. Estimated completion is 2023-08-02.
What interventions are being tested in trial NCT02799095?
The interventions under investigation include: ALKS 4230 (DRUG), ALKS 4230 + pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02799095?
This trial is sponsored by Mural Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02799095's enrollment target sits among peer trials
243 193rd of 2000 higher than 1,807 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06253871 · 243 participants · Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
- NCT06289491 · 243 participants · NA
A Trial of Hydrus Microstent Versus Goniotomy
- NCT06536296 · 243 participants · NA
The Impact of Music Medicine on Preterm Brain Development and Behavior
- NCT06907615 · 243 participants · Phase 2
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI